SG11201408617PA - Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders - Google Patents
Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disordersInfo
- Publication number
- SG11201408617PA SG11201408617PA SG11201408617PA SG11201408617PA SG11201408617PA SG 11201408617P A SG11201408617P A SG 11201408617PA SG 11201408617P A SG11201408617P A SG 11201408617PA SG 11201408617P A SG11201408617P A SG 11201408617PA SG 11201408617P A SG11201408617P A SG 11201408617PA
- Authority
- SG
- Singapore
- Prior art keywords
- alkyl
- international
- con
- treatment
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 January 2014 (03.01.2014) WIPOIPCT (10) International Publication Number WO 2014/001464 A1 (51) International Patent Classification: C07D 491/02 (2006.01) A61P 25/00 (2006.01) A61K31/4188 (2006.01) A61P 29/00 (2006.01) A61K35/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2013/063537 27 June 2013 (27.06.2013) English (30) Priority Data: 61/664,936 12174669.7 27 June 2012 (27.06.2012) 2 July 2012 (02.07.2012) English US EP (71) Applicant: 4SC DISCOVERY GMBH [DE/DE]; Am Klopferspitz 19a, 82152 Planegg-Martinsried (DE). (72) Inventors: LEBAN, Johann; Pyrkergasse 31, Appartment 10, A-1190 Wien (AT). ZAJA, Mirko; Horwarthstr. 33, 80804 Munchen (DE). (74) Agent: BOEHMERT & BOEHMERT; Hollerallee 32, 28209 Bremen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CAN CER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS Y L- <*) •t •t i-H o o o CJ O & (57) Abstract: The invention relates to a compound of the general formula (I) or a physiologically functional derivative, solvate or salt thereof, (I) wherein A is a bond, alkyl or alkoxy optionally substituted with one or more R\" as defined herein, *-N(R'\")CO-, *- CON(R'\")-, *-N(R\")CON(R\"')-, , -S-, -SO-, *-N(R'\")-, *-N(R'\")CO-, *-CON(R'\")-, -CO-, *-COO-, *-OOC-, *-S02N(R'\")-, -S0 , 2 or *- N(R'\")-S02-, wherein R'\" is as defined herein and * specifies the point of attachment to X; X is aryl, cycloalkyl, aralkyl, heterocyclyl or heteroaryl, which may be substituted with one or more R x further described herein; L is a bond or *-N(R )CO-, N *-CON(R )-, N *- N(R )-, N *-C=N(R )-, *-N(R )-alkyI-, *-alkyl-N(R )-, *-N(R )CON(R )-, *-CO-, *-S0 -, N N N N N 2 alkyl, *-alkyl-0-alkyl-, *-NCO-CH=CH-, *- CH=CH-CONH-, * -S0 N(R )-, *-N(R )S0 -, 2 N N 2 or heterocyclyl, wherein * specifies the point of attachment to X; Y is H, alkyl, aryl, aralkyl, cycloalkyl, heterocyclyl or heteroaryl, which may be substituted with one or more R Y further described herein; and R and R N are further described herein; as well as their use as a medicament, a pharmaceutical composition comprising them, method of a treat - ment or prevention of medical a condition entailing the administration thereof, and the use thereof in the manufacture of medica a - ment for the treatment or prevention of medical condition, particularly autoimmune a inflammatory disorders, CNS disorders, sleep - ing disorders, or proliferative diseases including cancer. The invention further relates to a specific process for the preparation of said compounds.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261664936P | 2012-06-27 | 2012-06-27 | |
EP12174669 | 2012-07-02 | ||
PCT/EP2013/063537 WO2014001464A1 (en) | 2012-06-27 | 2013-06-27 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408617PA true SG11201408617PA (en) | 2015-01-29 |
Family
ID=49782305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408617PA SG11201408617PA (en) | 2012-06-27 | 2013-06-27 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
Country Status (19)
Country | Link |
---|---|
US (2) | US9580438B2 (en) |
EP (1) | EP2867237A1 (en) |
JP (2) | JP6272846B2 (en) |
KR (1) | KR102155559B1 (en) |
CN (1) | CN104540831B (en) |
AU (2) | AU2013283318B2 (en) |
BR (1) | BR112014032581A8 (en) |
CA (1) | CA2877589C (en) |
EA (1) | EA029718B1 (en) |
HK (1) | HK1204474A1 (en) |
IL (1) | IL236463A0 (en) |
IN (1) | IN2014MN02562A (en) |
MX (1) | MX350418B (en) |
MY (1) | MY167785A (en) |
NZ (1) | NZ702618A (en) |
SG (1) | SG11201408617PA (en) |
UA (1) | UA116541C2 (en) |
WO (1) | WO2014001464A1 (en) |
ZA (1) | ZA201409194B (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014001464A1 (en) * | 2012-06-27 | 2014-01-03 | 4Sc Discovery Gmbh | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
CA2943220C (en) | 2014-03-20 | 2024-01-16 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
CN106661027B (en) | 2014-03-20 | 2019-12-24 | 卡佩拉医疗公司 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
WO2016028971A1 (en) | 2014-08-21 | 2016-02-25 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
WO2017013210A1 (en) * | 2015-07-21 | 2017-01-26 | 4Sc Ag | Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds |
US10590108B2 (en) | 2015-09-23 | 2020-03-17 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
HRP20220936T1 (en) * | 2016-04-07 | 2022-10-28 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
KR20200090154A (en) | 2017-10-27 | 2020-07-28 | 상하이 야오 유안 바이오테크놀로지 컴퍼니 리미티드 | Composition and method for modulating immune response by activation of alpha protein kinase 1 |
BR112021003665A2 (en) | 2018-09-13 | 2021-05-18 | Bayer Aktiengesellschaft | heterocyclene derivatives as pest control agents |
CN109020990A (en) * | 2018-09-20 | 2018-12-18 | 广西壮族自治区药用植物园 | Phenyl benzofurans compound, and preparation method thereof, composition and medical usage |
KR102119150B1 (en) * | 2018-10-23 | 2020-06-04 | 한국원자력의학원 | A pharmaceutical composition for preventing or treating cancer comprising as an active ingredient N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl) |
WO2020132582A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting agonists and uses thereof |
JP7327855B2 (en) | 2020-06-26 | 2023-08-16 | ラクオリア創薬株式会社 | METHOD FOR SELECTING CANCER PATIENTS FOR EFFECTIVE RETINOID AND CANCER THERAPEUTIC COMBINATION THERAPY AND COMBINATION MEDICINE OF RETINOID AND CANCER THERAPEUTIC |
CN116942819A (en) * | 2023-04-24 | 2023-10-27 | 珠海市人民医院 | Application of microtubule-associated serine/threonine-like kinase inhibitor in preparation of medicines for treating tumors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4167569A (en) | 1976-12-09 | 1979-09-11 | Imperial Chemical Industries Limited | Pyrimido[1,2-a ]benzimidazole derivatives |
ATE511840T1 (en) | 2001-10-09 | 2011-06-15 | Amgen Inc | IMIDAZOLE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS |
US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
JO2724B1 (en) | 2004-08-19 | 2013-09-15 | افينتس فارماسوتيكالز انك | 3-substituted-5- and 6-Aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase I |
WO2006130673A1 (en) * | 2005-05-31 | 2006-12-07 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
EP1957078B1 (en) | 2005-12-02 | 2013-08-28 | Bayer HealthCare, LLC | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
PE20080403A1 (en) * | 2006-07-14 | 2008-04-25 | Amgen Inc | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE |
FR2918061B1 (en) | 2007-06-28 | 2010-10-22 | Sanofi Aventis | 6-CYCLOAMINO-3- (PYRIDIN-4-YL) IMIDAZO-1,2-B1-PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE. |
WO2009047163A1 (en) | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
SG10201501272SA (en) * | 2009-10-22 | 2015-04-29 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
WO2014001464A1 (en) * | 2012-06-27 | 2014-01-03 | 4Sc Discovery Gmbh | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
-
2013
- 2013-06-27 WO PCT/EP2013/063537 patent/WO2014001464A1/en active Application Filing
- 2013-06-27 UA UAA201500560A patent/UA116541C2/en unknown
- 2013-06-27 CN CN201380034461.4A patent/CN104540831B/en not_active Expired - Fee Related
- 2013-06-27 EP EP13731822.6A patent/EP2867237A1/en not_active Withdrawn
- 2013-06-27 MY MYPI2014003556A patent/MY167785A/en unknown
- 2013-06-27 AU AU2013283318A patent/AU2013283318B2/en not_active Ceased
- 2013-06-27 BR BR112014032581A patent/BR112014032581A8/en not_active Application Discontinuation
- 2013-06-27 EA EA201500050A patent/EA029718B1/en not_active IP Right Cessation
- 2013-06-27 IN IN2562MUN2014 patent/IN2014MN02562A/en unknown
- 2013-06-27 CA CA2877589A patent/CA2877589C/en not_active Expired - Fee Related
- 2013-06-27 MX MX2014015938A patent/MX350418B/en active IP Right Grant
- 2013-06-27 KR KR1020157001782A patent/KR102155559B1/en active IP Right Grant
- 2013-06-27 JP JP2015519098A patent/JP6272846B2/en not_active Expired - Fee Related
- 2013-06-27 US US14/411,795 patent/US9580438B2/en active Active
- 2013-06-27 SG SG11201408617PA patent/SG11201408617PA/en unknown
- 2013-06-27 NZ NZ702618A patent/NZ702618A/en not_active IP Right Cessation
-
2014
- 2014-12-12 ZA ZA2014/09194A patent/ZA201409194B/en unknown
- 2014-12-25 IL IL236463A patent/IL236463A0/en unknown
-
2015
- 2015-05-26 HK HK15105006.4A patent/HK1204474A1/en unknown
-
2017
- 2017-02-27 US US15/443,180 patent/US20170240556A1/en not_active Abandoned
-
2018
- 2018-01-04 JP JP2018000285A patent/JP2018076360A/en active Pending
- 2018-02-22 AU AU2018201275A patent/AU2018201275A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IN2014MN02562A (en) | 2015-07-24 |
HK1204474A1 (en) | 2015-11-20 |
AU2018201275A1 (en) | 2018-03-15 |
MX350418B (en) | 2017-09-06 |
EA029718B1 (en) | 2018-05-31 |
CN104540831A (en) | 2015-04-22 |
JP2015525742A (en) | 2015-09-07 |
BR112014032581A8 (en) | 2018-08-14 |
KR102155559B1 (en) | 2020-09-15 |
NZ702618A (en) | 2016-12-23 |
WO2014001464A1 (en) | 2014-01-03 |
JP6272846B2 (en) | 2018-01-31 |
US20150158878A1 (en) | 2015-06-11 |
EP2867237A1 (en) | 2015-05-06 |
EA201500050A1 (en) | 2015-09-30 |
US9580438B2 (en) | 2017-02-28 |
CN104540831B (en) | 2017-11-07 |
MY167785A (en) | 2018-09-25 |
BR112014032581A2 (en) | 2017-06-27 |
CA2877589A1 (en) | 2014-01-03 |
MX2014015938A (en) | 2015-07-21 |
JP2018076360A (en) | 2018-05-17 |
CA2877589C (en) | 2019-11-26 |
ZA201409194B (en) | 2017-08-30 |
IL236463A0 (en) | 2015-02-26 |
US20170240556A1 (en) | 2017-08-24 |
AU2013283318B2 (en) | 2017-11-23 |
KR20150037877A (en) | 2015-04-08 |
AU2013283318A1 (en) | 2015-01-22 |
UA116541C2 (en) | 2018-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
SG11201900077QA (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
SG11201408094YA (en) | Neprilysin inhibitors | |
SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11202000266VA (en) | Quinoline derivatives for treating infections with helminths | |
SG11201809342YA (en) | Pyrimidine compounds as jak kinase inhibitors | |
SG11201407837WA (en) | Beta-hairpin peptidomimetics | |
SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
SG11201903326RA (en) | Liposomal formulation for use in the treatment of cancer | |
SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
SG11201908729UA (en) | Phenyl derivatives as pge2 receptor modulators | |
SG11201402986RA (en) | Kinase inhibitors | |
SG11201804223TA (en) | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF | |
SG11201901817SA (en) | Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors | |
SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
SG11201809674QA (en) | Adenine derivatives as protein kinase inhibitors | |
SG11201908235RA (en) | An isoxazole derivatives as nuclear receptor agonists and used thereof | |
SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor | |
SG11201805142RA (en) | Pharmaceutical compositions comprising phenylaminopyrimidine derivative |